Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 9;69(11):e20230727.
doi: 10.1590/1806-9282.20230727. eCollection 2023.

Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae

Uğur Önal  1 , Nazmiye Ülkü Tüzemen  2 , Pınar Küçükdemirci Kaya  3 , Remzi İşçimen  3 , Nermin Kelebek Girgin  3 , Cüneyt Özakın  2 , Ferda Şöhret Kahveci  3 , Halis Akalın  1
Affiliations

Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae

Uğur Önal et al. Rev Assoc Med Bras (1992). .

Abstract

Objective: The aim of this study was to evaluate the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae infections in a tertiary-care center.

Methods: Between December 24, 2018 and November 21, 2022, adult patients diagnosed with bloodstream infection or ventilator-associated pneumonia due to culture-confirmed carbapenem-resistant Klebsiella pneumoniae in the anesthesiology and reanimation intensive care units were investigated retrospectively.

Results: There were a total of 62 patients fulfilling the study inclusion criteria. No significant difference was recorded in 14- and 30-day mortality among different types of combination regimens such as fosfomycin plus one or two antibiotic combinations. Hypokalemia (OR:5.651, 95%CI 1.019-31.330, p=0.048) was found to be a significant risk factor for 14-day mortality, whereas SOFA score at the time of diagnosis (OR:1.497, 95%CI 1.103-2.032, p=0.010) and CVVHF treatment (OR:6.409, 95%CI 1.395-29.433, p=0.017) were associated with 30-day mortality in multivariate analysis.

Conclusion: In our study, high mortality rates were found in patients with bloodstream infection or ventilator-associated pneumonia due to carbapenem-resistant Klebsiella pneumoniae, and no significant difference was recorded in 14- and 30-day mortality among different types of combination regimens such as fosfomycin plus one or two antibiotic combinations.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: the authors declare there is no conflicts of interest.

References

    1. Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis. 2022;22(3):401–412. doi: 10.1016/S1473-3099(21)00399-6. - DOI - PMC - PubMed
    1. Savoldi A, Carrara E, Piddock LJV, Franceschi F, Ellis S, Chiamenti M, et al. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies. BMC Infect Dis. 2021;21(1):545–545. doi: 10.1186/s12879-021-06253-x. - DOI - PMC - PubMed
    1. Centres for Disease Control and Prevention [CDC] National healthcare safety network (NHSN) patient safety component manual. 2023. [cited on 2023 Mar 10]. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_current.pdf .
    1. Karakuzu Z, Iscimen R, Akalin H, Kelebek Girgin N, Kahveci F, Sinirtas M. Prognostic risk factors in ventilator-associated pneumonia. Med Sci Monit. 2018;24:1321–1328. doi: 10.12659/msm.905919. - DOI - PMC - PubMed
    1. Centres for Disease Control and Prevention [CDC] People who are immunocompromised. 2023. [cited on 2023 Mar 10]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-... .